Skip to main content
Top
Published in: Digestive Diseases and Sciences 4/2012

01-04-2012 | Correspondence

Letter in Response to the Recently Published Study: Prophylactic Pancreatic Stents: Does Size Matter? A Comparison of 4-Fr and 5-Fr Stents in Reference to Post-ERCP Pancreatitis and Migration Rate

Authors: Prabhleen Chahal, Todd H. Baron

Published in: Digestive Diseases and Sciences | Issue 4/2012

Login to get access

Excerpt

We read with great interest the study published by Al-Kawas et al. [1] regarding migration rates of 5-Fr and 4-Fr pancreatic duct stents. However, we disagree with the main conclusions of the study, namely the migration rates and post-ERCP pancreatitis rates. It is known that pancreatic stents with intraductal flanges and those of longer length have a lower spontaneous migration rate. In their study, the authors failed to provide the readers with pertinent information about the number of 5-Fr stents with intraductal flanges and stent length. In patients who received 5-Fr stents, there was a wide range of lengths from 2 to 11 cm, though the number of each length is not mentioned. These stent-related factors impact the spontaneous dislodgement rates; the authors pooled the data from these vastly different stent lengths into one group and concluded that the spontaneous dislodgement rate was significantly lower than that compared to a group who received 4-Fr pancreatic stents without an intraductal flange and of undisclosed, presumably uniform lengths. …
Literature
1.
go back to reference Pahk A, Rigaux J, Poreddy V, Smith J, Al-Kawas F. Prophylactic pancreatic stents: Does size matter? A comparison of 4-Fr and 5-Fr stents in reference to post-ERCP pancreatitis and migration rate. Dig Dis Sci. 2011;56:3058–3064.PubMedCrossRef Pahk A, Rigaux J, Poreddy V, Smith J, Al-Kawas F. Prophylactic pancreatic stents: Does size matter? A comparison of 4-Fr and 5-Fr stents in reference to post-ERCP pancreatitis and migration rate. Dig Dis Sci. 2011;56:3058–3064.PubMedCrossRef
2.
go back to reference Chahal P, Baron TH, Petersen BT, Topazian MD, Gostout CJ, Levy MJ. Pancreatic stent prophylaxis of post endoscopic retrograde cholangiopancreatography pancreatitis: spontaneous migration rates and clinical outcomes. Minerva Gastroenterol Dietol. 2007;53:225–230.PubMed Chahal P, Baron TH, Petersen BT, Topazian MD, Gostout CJ, Levy MJ. Pancreatic stent prophylaxis of post endoscopic retrograde cholangiopancreatography pancreatitis: spontaneous migration rates and clinical outcomes. Minerva Gastroenterol Dietol. 2007;53:225–230.PubMed
3.
go back to reference Chahal P, Tarnasky PR, Petersen BT, et al. Short 5-Fr vs long 3-Fr pancreatic stents in patients at risk for post-endoscopic retrograde cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol. 2009;7:834–839.PubMedCrossRef Chahal P, Tarnasky PR, Petersen BT, et al. Short 5-Fr vs long 3-Fr pancreatic stents in patients at risk for post-endoscopic retrograde cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol. 2009;7:834–839.PubMedCrossRef
4.
go back to reference Rashdan A, Fogel EL, McHenry L Jr, Sherman S, Temkit M, Lehman GA. Improved stent characteristics for prophylaxis of post ERCP pancreatitis. Clin Gastroenterol Hepatol. 2004;2:322–329.PubMedCrossRef Rashdan A, Fogel EL, McHenry L Jr, Sherman S, Temkit M, Lehman GA. Improved stent characteristics for prophylaxis of post ERCP pancreatitis. Clin Gastroenterol Hepatol. 2004;2:322–329.PubMedCrossRef
Metadata
Title
Letter in Response to the Recently Published Study: Prophylactic Pancreatic Stents: Does Size Matter? A Comparison of 4-Fr and 5-Fr Stents in Reference to Post-ERCP Pancreatitis and Migration Rate
Authors
Prabhleen Chahal
Todd H. Baron
Publication date
01-04-2012
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2012
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2063-1

Other articles of this Issue 4/2012

Digestive Diseases and Sciences 4/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.